Stress and radiation-induced activation of multiple intracellular signaling pathways

Radiation Research

Volumn 159, Issue 3, 2003, Pages 283-300

  Dent, Paul ^a   Yacoub, Adly ^a   Contessa, Joseph ^a   Caron, Ruben ^a   Amorino, George ^a   Valerie, Kristoffer ^a   Hagan, Michael P ^a   Grant, Steven ^a   Schmidt Ullrich, Rupert ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; INTERLEUKIN 6; LIGAND; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; NITROGEN; PHOSPHATASE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; RAF PROTEIN; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; TUMOR NECROSIS FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

AMINO ACID SUBSTITUTION; ANIMAL CELL; APOPTOSIS; CELL COMMUNICATION; CELL CYCLE G2 PHASE; CELL GROWTH; CELL INTERACTION; CELL PROTECTION; CELL STIMULATION; CELL SURVIVAL; CELL TYPE; CONFERENCE PAPER; DEGRADATION KINETICS; GENE MUTATION; HUMAN; ONCOGENE RAS; PARACRINE SIGNALING; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; PROTO ONCOGENE; RADIATION DOSE; RADIATION EXPOSURE; RADIATION MUTAGENESIS; RADIATION PROTECTION; RADIATION RESPONSE; SIGNAL TRANSDUCTION; STRESS; ULTRAVIOLET RADIATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CELL DIVISION; CELL NUCLEUS; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASES; MODELS, BIOLOGICAL; NEOPLASMS; ONCOGENE PROTEINS V-ERBB; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 0037335568     PISSN: 00337587     EISSN: None     Source Type: Journal    
DOI: 10.1667/0033-7587(2003)159[0283:SARIAO]2.0.CO;2     Document Type: Conference Paper

References (256)

1. A. A. Green, G. T. Cori and C. F. Cori, Crystalline muscle phosphorylase. J. Biol. Chem. 142, 447-448 (1942).
2. G. T. Cori and C. F. Cori, The enzymatic conversion of phosphorylase a to b. J. Biol. Chem. 158, 321-332 (1945).
3. E. W. Sutherland, The biological role of cyclic AMP. J. Am. Med. Assoc. 214, 1281-1288 (1970).
4. E. G. Krebs and E. H. Fisher, The phosphorylase b to a converting enzyme of rabbit skeletal muscle. Biochim. Biophys. Acta 20, 150-157 (1956).
5. D. P. Wolf, E. H. Fischer and E. G. Krebs, Amino acid sequence of the phosphorylated site in rabbit liver glycogen phosphorylase. Biochemistry 9, 1923-1929 (1970).
6. D. A. Walsh, J. P. Perkins and E. G. Krebs, An adenosine 3′,5′-monophosphate-dependent protein kinase from rabbit skeletal muscle. J. Biol. Chem. 243, 3763-3775 (1968).
7. L. F. Leloir, Regulation of glycogen metabolism. Natl. Cancer Inst. Monogr. 27, 3-18 (1967).
8. J. Larner, Covalent and noncovalent control of glycogen synthesis. Ann. NY Acad. Sci. 210, 207-214 (1973).
9. 2+. J. Biol. Chem. 246, 1961-1967 (1971).
10. 2+-dependent protein phosphorylation system in membranes from various tissues, and its activation by "calcium-dependent regulator". Proc. Natl. Acad. Sci. USA 75, 5432-5436 (1978).
11. M. Freissmuth, P. J. Casey and A. G. Gilman, G proteins control diverse pathways of transmembrane signaling. FASEB J. 10, 2125- 2131 (1989).
12. M. J. Berridge, J. P. Heslop, R. F. Irvine and K. D. Brown, Inositol trisphosphate formation and calcium mobilization in Swiss 3T3 cells in response to platelet-derived growth factor. Biochem. J. 222, 195-201 (1984).
13. J. R. Williamson, R. H. Cooper, S. K. Joseph and A. P. Thomas, Inositol trisphosphate and diacylglycerol as intracellular second messengers in liver. Am. J. Physiol. 248, C203-216 (1985).
14. M. S. Collett, A. F. Purchio and R. L. Erikson, Avian sarcoma virus-transforming protein, pp60src shows protein kinase activity specific for tyrosine. Nature 285, 167-169 (1980).
15. L. F. Parada, C. J. Tabin, C. Shih and R. A. Weinberg, Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene. Nature 297, 474-478 (1982).
16. T. W. Sturgill and L. B. Ray, Muscle proteins related to microtubule associated protein-2 are substrates for an insulin-stimulatable kinase. Biochem. Biophys. Res. Commun. 134, 565-571 (1986).
17. T. G. Boulton and M. H. Cobb, Identification of multiple extracellular signal-regulated kinases (ERKs) with antipeptide antibodies. Cell Regul. 2, 357-371 (1991).
18. T. W. Sturgill, L. B. Ray, E. Erikson and J. L. Maller, Insulin-stimulated MAP-2 kinase phosphorylates and activates ribosomal protein S6 kinase II. Nature 334, 715-718 (1988).
19. J. Wu, H. Michel, A. Rossomando, T. Haystead, J. Shabanowitz, D. F. Hunt and T. W. Sturgill, Renaturation and partial peptide sequencing of mitogen-activated protein kinase (MAP kinase) activator from rabbit skeletal muscle. Biochem. J. 285, 701-705 (1992).
20. C. M. Haystead, J. Wu, P. Gregory, T. W. Sturgill and T. A. Haystead, Functional expression of a MAP kinase kinase in COS cells and recognition by an anti-STE7/byr1 antibody. FEBS Lett. 317, 12-16 (1993).
21. D. J. Robbins, E. Zhen, H. Owaki, C. A. Vanderbilt, D. Ebert, T. D. Geppert and M. H. Cobb, Regulation and properties of extra-cellular signal-regulated protein kinases 1 and 2 in vitro. J. Biol. Chem. 268, 5097-5106 (1993).
22. J. Wu, J. K. Harrison, P. Dent, K. R. Lynch, M. J. Weber and T. W. Sturgill, Identification and characterization of a new mammalian mitogen-activated protein kinase kinase, MKK2. Mol. Cell Biol. 13, 4539-4548 (1993).
23. J. M. Kyriakis, H. App, X. F. Zhang, P. Banerjee, D. L. Brautigan, U. R. Rapp and J. Avruch, Raf-1 activates MAP kinase-kinase. Nature 358, 417-421 (1992).
24. P. Dent, W. Haser, T. A. Haystead, L. A. Vincent, T. M. Roberts and T. W. Sturgill, Activation of mitogen-activated protein kinase kinase by v-Raf in NIH 3T3 cells and in vitro. Science 257, 1404-1407 (1992).
25. T. A. Navas, D. T. Baldwin and T. A. Stewart, RIP2 is a Raf1-activated mitogen-activated protein kinase kinase. J. Biol. Chem. 274, 33684-33690 (1999).
26. E. Bosch, H. Cherwinski, D. Peterson and M. McMahon, Mutations of critical amino acids affect the biological and biochemical properties of oncogenic A-Raf and Raf-1. Oncogene 15, 1021-1033 (1997).
27. R. Marais, Y. Light, H. F. Paterson, C. S. Mason and C. J. Marshall, Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J. Biol. Chem. 272, 4378-4383 (1997).
28. R. K. Schmidt-Ullrich, R. B. Mikkelsen, P. Dent, D. G. Todd, K. Valerie, B. D. Kavanagh, J. N. Contessa, W. K. Rorrer and P. B. Chen, Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15, 1191-1197 (1997).
29. S. A. Moodie, B. M. Willumsen, M. J. Weber and A. Wolfman, Complexes of Ras. GTP with Raf-1 and mitogen-activated protein kinase kinase. Science 260, 1658-1661 (1993).
30. L. Van Aelst, M. Barr, S. Marcus, A. Polverino and M. Wigler, Complex formation between RAS and RAF and other protein kinases. Proc. Natl. Acad. Sci. USA 90, 6213-6217 (1993).
31. S. J. Leevers, H. F. Paterson and C. J. Marshall, Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369, 411-414 (1994).
32. 6-Raf-1 in vitro by partially purified plasma membranes from v-Ras-transformed and serum stimulated fibroblasts. Proc. Natl. Acad. Sci. USA 91, 9544-9548 (1994).
33. C. G. Broustas, N. Grammatikakis, M. Eto, P. Dent, D. L. Brautigan and U. Kasid, Phosphorylation of the myosin-binding subunit of myosin phosphatase by Raf-1 and inhibition of phosphatase activity. J. Biol. Chem. 277, 3053-3059 (2002).
34. J. Chen, K. Fujii, L. Zhang, T. Roberts and H. Fu, Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proc. Natl. Acad. Sci. USA 98, 7783-7788 (2001).
35. D. Stokoe and F. McCormick, Activation of c-Raf-1 by Ras and Src through different mechanisms: Activation in vivo and in vitro. EMBO J. 16, 2384-2396 (1997).
36. G. Tzivion, J. Luo and J. Avruch, A dimeric 14-3-3 protein is an essential cofactor for Raf kinase activity. Nature 394, 88-92 (1998).
37. J. A. Thorson, L. W. K. Yu, A. L. Hsu, N. Y. Shih, P. R. Graves, J. W. Tanner, P. M. Allen, H. Piwnica-Worms and A. S. Shaw, 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol. Cell. Biol. 18, 5229-5238 (1998).
38. R. A. McPherson, A. Harding, S. Roy, A. Lane and J. F. Hancock, Interactions of c-Raf-1 with phosphatidylserine and 14-3-3. Oncogene 18, 3862-3869 (1999).
39. M. T. Yip-Schneider, W. Miao, A. Lin, D. S. Barnard, G. Tzivion and M. S. Marshall, Regulation of the Raf-1 kinase domain by phosphorylation and 14-3-3 association. Biochem. J. 351, 151-159 (2000).
40. M. Jaumot and J. F. Hancock, Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20, 3949-3958 (2001).
41. H. Sun, A. J. King, H. B. Diaz and M. S. Marshall, Regulation of the protein kinase Raf-1 by oncogenic Ras through phosphatidylinositol 3-kinase, Cdc42/Rac and Pak. Curr. Biol. 10, 281-284 (2000).
42. Y. Zhang, B. Yao, S, Delikat, S. Bayoumy, X. H. Lin, S. Basu, M. McGinley, P. Y. Chan-Hui, H. Lichenstein and R. Kolesnick, Kinase suppressor of Ras is ceramide-activated protein kinase. Cell 89, 63-72 (1997).
43. G. Muller, P. Storz, S. Bourteele, H. Doppler, K. Pfizenmaier, H. Mischak, A. Philipp, C. Kaiser and W. Kolch, Regulation of Raf-1 kinase by TNF via its second messenger ceramide and cross-talk with mitogenic signalling. EMBO J. 17, 732-742 (1998).
44. J. R. Fabian, I. O. Daar and D. K. Morrison, Critical tyrosine residues regulate the enzymatic and biological activity of Raf-1 kinase. Mol. Cell Biol. 13, 7170-7179 (1993).
45. P. Dent, T. Jelinek, D. K. Morrison, M. J. Weber and T. W. Sturgill, Reversal of Raf-1 activation by purified and membrane associated protein phosphatases. Science 268, 1902-1906 (1995).
46. R. Marais, Y. Light, H. F. Paterson and C. J. Marshall, Ras recruits Raf-1 to the plasma membrane for activation by tyrosine phosphorylation. EMBO J. 14, 3136-3145 (1995).
47. D. C. Schonwasser, R. M. Marais, C. J. Marshall and P. J. Parker, Activation of the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway by conventional, novel, and atypical protein kinase C isotypes. Mol. Cell Biol. 18, 790-798 (1998).
48. H. Cai, U. Smola, V. Wixler, I. Eisenmann-Tappe, M. T. Diaz-Meco, J. Moscat, U. Rapp and G. M. Cooper, Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol. Cell Biol. 17, 732-741 (1997).
49. S. Zimmermann and K. Moelling, Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286, 1741-1744 (1999).
50. H. P. Reusch, S. Zimmermann, M. Schaefer, M. Paul and K. Moelling, Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J. Biol. Chem. 276, 33630-33637 (2001).
51. N. Li, A. Batzer, R. Daly, V. Yajnik, E. Skolnik, P. Chardin, D. BarSagi, B. Margolis and J. Schlessinger, Guanine-nucleotide-releasing factor hSos1 binds to Grb2 and links receptor tyrosine kinases to Ras signaling. Nature 363, 85-88 (1993).
52. J. P. Olivier, T. Raabe, M. Henkemeyer, B. Dickson, G. Mbamalu, B. Margolis, J. Schlessinger, E. Hafen and T. Pawson, A Drosophila SH2-SH3 adaptor protein implicated in coupling the sevenless tyrosine kinase to an activator of Ras guanine nucleotide exchange, Sos. Cell 73, 179-191 (1993).
53. M. I. Wahl, S. Nishibe and G. Carpenter, Growth factor signaling pathways: Phosphoinositide metabolism and phosphorylation of phospholipase C. Cancer Cells 1, 101-107 (1989).
54. R. A. Frye, Involvement of G proteins, cytoplasmic calcium, phospholipases, phospholipid-derived second messengers, and protein kinases in signal transduction from mitogenic cell surface receptors. Cancer Treat. Res. 63, 281-299 (1992).
55. + in vascular smooth muscle. J. Hypertens. 12 (Suppl.), S133-S143 (1994).
56. D. Y. Noh, S. H. Shin and S. G. Rhee, Phosphoinositide-specific phospholipase C and mitogenic signaling. Biochim. Biophys. Acta 1242, 99-113 (1995).
57. B. Vanhaesebroeck and D. R. Alessi, The PI3K-PDK1 connection: More than just a road to PKB. Biochem. J. 346, 561-576 (2000).
58. M. P. Wymann and L. Pirola, Structure and function of phospho-inositide 3-kinases. Biochim. Biophys. Acta 1436, 127-150 (1998).
59. T. T. Ching, H. P. Lin, C. C. Yang, M. Oliveira, P. J. Lu and C. S. Chen, Specific binding of the C-terminal Src homology 2 domain of the p85α subunit of phosphoinositide 3-kinase to phosphatidylinositol 3,4,5-trisphosphate. Localization and engineering of the phosphoinositide-binding motif. J. Biol. Chem. 276, 43932-43938 (2001).
60. H. Lee, R. W. Akita, M. X. Sliwkowski and N. J. Maihle, A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4. Cancer Res. 61, 4467-4473 (2001).
61. C. F. Yu, B. Roshan, Z. X. Liu and L. G. Cantley, Erk regulates the hepatocyte growth factor-mediated interaction of gab1 and the phosphatidylinositol 3-kinase. J. Biol. Chem. 276, 32552-32558 (2001).
62. D. H. Van-Weering, J. de Rooij, B. Marte, J. Downward, J. L. Bos and B. M. Burgering, Protein kinase B activation and lamellipodium formation are independent phosphoinositide 3-kinase-mediated events differentially regulated by endogenous Ras. Mol. Cell Biol. 18, 1802-1811 (1998).
63. H. Gu, H. Maeda, J. J. Moon, J. D. Lord, M. Yoakim, B. H. Nelson and B. G. Neel, New role for Shc in activation of the phosphatidylinositol 3-kinase/Akt pathway. Mol. Cell Biol. 20, 7109-7120 (2000).
64. I. Rubio, P. Rodriguez-Viciana, J. Downward and R. Wetzker, Interaction of Ras with phosphoinositide 3-kinase gamma. Biochem. J. 326, 891-895 (1997).
65. N. Filippa, C. L. Sable, B. A. Hemmings and E. Van Obberghen, Effect of phosphoinositide-dependent kinase 1 on protein kinase B translocation and its subsequent activation. Mol. Cell Biol. 20, 5712-5721 (2000).
66. J. Park, M. M. Hill, D. Hess, D. P. Brazil, J. Hofsteenge and B. A. Hemmings, Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 (PDK1) and their role in regulating kinase activity. J. Biol. Chem. 276, 37459-37471 (2001).
67. L. Simpson and R. Parsons, PTEN: Life as a tumor suppressor. Exp. Cell Res. 264, 29-41 (2001).
68. D. Bonneau and M. Longy, Mutations of the human PTEN gene. Hum. Mutat. 16, 109-122 (2000).
69. R. Wechsler-Reya and M. P. Scott, The developmental biology of brain tumors. Annu. Rev. Neurosci. 24, 385-428 (2001).
70. D. Haas-Kogan, N. Shalev, M. Wong, G. Mills, G. Yount and D. Stokoe, Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr. Biol. 8, 1195-1198 (1998).
71. A. Balendran, G. R. Hare, A. Kieloch, M. R. Williams and D. R. Alessi, Further evidence that 3-phosphoinositide-dependent protein kinase-1 (PDK1) is required for the stability and phosphorylation of protein kinase C (PKC) isoforms. FEBS Lett. 484, 217-223 (2000).
72. D. A. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich and B. A. Hemmings, Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789 (1995).
73. D. R. Alessi, F. B. Caudwell, M. Andjelkovic, B. A. Hemmings and P. Cohen, Molecular basis for the substrate specificity of protein kinase B; comparison with MAPKAP kinase-1 and p70 S6 kinase. FEBS Lett. 399, 333-338 (1996).
74. +/- mice. Proc. Natl. Acad. Sci. USA 98, 10320-10325 (2001).
75. L. M. Dickson, M. K. Lingohr, J. McCuaig, S. R. Hugl, L. Snow, B. B. Kahn, M. G. Myers and C. J. Rhodes, Differential activation of protein kinase B and p70(S6)K by glucose and insulin-like growth factor 1 in pancreatic beta-cells (INS-1). J. Biol. Chem. 276, 21110-21120 (2001).
76. M. Andjelkovic, S. M. Maira, P. Cron, P. J. Parker and B. A. Hemmings, Domain swapping used to investigate the mechanism of protein kinase B regulation by 3-phosphoinositide-dependent protein kinase 1 and Ser473 kinase. Mol. Cell. Biol. 19, 5061-5072 (1999).
77. M. J. Rane, P. Y. Coxon, D. W. Powell, R. Webster, J. B. Klein, W. Pierce, P. Ping and K. R. McLeish, p38 Kinase-dependent MAP- KAPK-2 activation functions as 3-phosphoinositide-dependent kinase-2 for Akt in human neutrophils. J. Biol. Chem. 276, 3517- 3523 (2001).
78. R. Chen, O. Kim, J. Yang, K. Sato, K. M. Eisenmann, J. McCarthy, H. Chen and Y. Qiu, Regulation of Akt/PKB activation by tyrosine phosphorylation. J. Biol. Chem. 276, 31858-31862 (2001).
79. M. Hibi, A. Lin, T. Smeal, A. Minden and M. Karin, Identification of an oncoprotein- and UV-responsive protein kinase that binds and potentiates the c-Jun activation domain. Genes. Dev. 7, 2135-2148 (1993).
80. B. Derijard, M. Hibi, I. H. Wu, T. Barrett, B. Su, T. Deng, M. Karin and R. J. Davis, JNK1: A protein kinase stimulated by UV light and Ha-Ras that binds and phosphorylates the c-Jun activation domain. Cell 76, 1025-1037 (1994).
81. R. J. Davis, Signal transduction by the c-Jun N-terminal kinase. Biochem. Soc. Symp. 64, 1-12 (1999).
82. S. H. Yang, A. J. Whitmarsh, R. J. Davis and A. D. Sharrocks, Differential targeting of MAP kinases to the ETS-domain transcription factor Elk-1. EMBO J. 17, 1740-1749 (1998).
83. K. Noguchi, C. Kitanaka, H. Yamana, A. Kokubu, T. Mochizuki and Y. Kuchino, Regulation of c-Myc through phosphorylation at Ser-62 and Ser-71 by c-Jun N-terminal kinase. J. Biol. Chem. 274, 32580-32587 (1999).
84. B. Derijard, J. Raingeaud, T. Barrett, I. H. Wu, J. Han, R. J. Ulevitch and R. J. Davis, Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms. Science 267, 682-685 (1995).
85. C. Tournier, A. J. Whitmarsh, J. Cavanagh, T. Barrett and R. J. Davis, The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases. Mol. Cell. Biol. 19, 1569-1581 (1999).
86. T. K. Schlesinger, G. R. Fanger, T. Yujiri and G. L. Johnson, The TAO of MEKK. Front. Biosci. 3, D1181-D1186 (1998).
87. J. T. Yustein, D. Li, D. Robinson and H. J. Kung, KFC, a Ste20-like kinase with mitogenic potential and capability to activate the SAPK/JNK pathway. Oncogene 19, 710-718 (2000).
88. I. Timokhina, H. Kissel, G. Stella and P. Besmer, Kit signaling through PI 3-kinase and Src kinase pathways: An essential role for Racl and JNK activation in mast cell proliferation. EMBO J. 17, 6250-6262 (1998).
89. Z. Assefa, M. Valius, T. Vantus, P. Agostinis, W. Merlevede and J. R. Vandenheede, JNK/SAPK activation by platelet-derived growth factor in A431 cells requires both the phospholipase C-gamma and the phosphatidylinositol 3-kinase signaling pathways of the receptor. Biochem. Biophys. Res. Commun. 261, 641-645 (1999).
90. Y. Lu and J. Settleman, The Drosophila Pkn protein kinase is a Rho/Rac effector target required for dorsal closure during embryogenesis. Genes Dev. 13, 1168-1180 (1999).
91. J. Han, J. D. Lee, L. Bibbs and R. J. Ulevitch, A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science 265, 808-811 (1994).
92. A. Lin, A. Minden, H. Martinetto, F. X. Claret, C. Lange-Carter, F. Mercurio, G. L. Johnson and M. Karin, Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. Science 268, 286-290 (1995).
93. N. J. Holbrook, Y. Liu and A. J. Fornace, Signaling events controlling the molecular response to genotoxic stress. EXS 77, 273-288 (1996).
94. S. H. Lee, M. Eom, S. J. Lee, S. Kim, H. J. Park and D. Park, BetaPix-enhanced p38 activation by Cdc42/Rac/PAK/MKK3/6-mediated pathway. Implication in the regulation of membrane ruffling. J. Biol. Chem. 276, 25066-25072 (2001).
95. J. M. Kyriakis and J. Avruch, Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81, 807-869 (2001).
96. E. T. Maizels, A. Mukherjee, A. Sithanandam, C. A. Peters, J. Cottom, K. E. Mayo and M. Hunzicker-Dunn, Developmental regulation of mitogen-activated protein kinase-activated kinases-2 and -3 (MAPKAPK-2/-3) in vivo during corpus luteum formation in the rat. Mol. Endocrinol. 15, 716-733 (2001).
97. M. M. Deak, A. D. Clifton, L. M. Lucocq and D. R. Alessi, Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB. EMBO J. 17, 4426-4441 (1998).
98. G. R Wiggin, A. Soloaga, J. M. Foster, V. Murray-Tait, P. Cohen and J. S. Arthur, MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts. Mol. Cell. Biol. 22, 2871-2881 (2002).
99. K. Kato, H. Ito, I. Iwamoto, K. Lida and Y. Inaguma, Protein kinase inhibitors can suppress stress-induced dissociation of Hsp27. Cell Stress Chaperones 6, 16-20 (2001).
100. G. Yosimichi, T. Nakanishi, T. Nishida, T. Hattori, T. Takano-Yamamoto and M. Takigawa, CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur. J. Biochem. 268, 6058-6065 (2001).
101. N. Juretic, J. F. Santibanez, C. Hurtado and J. Martinez, ERK 1, 2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line. J. Cell. Biochem. 83, 92-98 (2001).
102. W. L. Liu, X. Guo, Q. Q. Chen and Z. G. Guo, Opposing effect of p38 and p44/42 signaling on TNF-α-induced apoptosis in bovine aortic endothelial cells. Acta Pharmacol. Sin. 22, 405-410 (2001).
103. S. J. Kim, J. W. Ju, C. D. Oh, Y. M. Yoon, W. K. Song, J. H. Kim, Y. J. Yoo, O. S. Bang, S. S. Kang and J. S. Chun, ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status. J. Biol. Chem. 277, 1332-1339 (2002).
104. M. M. Taher, C. M. Hershey, J. D. Oakley and K. Valerie, Role of the p38 and MEK-1/2/p42/44 MAP kinase pathways in the differential activation of human immunodeficiency virus gene expression by ultraviolet and ionizing radiation. Photochem. Photobiol. 71, 455-459 (2000).
105. 2-M arrest. Cell Growth Differ. 13, 237-246 (2002).
106. X. Wang, C. H. McGowan, M. Zhao, L. He, J. S. Downey, C. Fearns, Y. Wang, S. Huang and J. Han, Involvement of the MKK6-p38γ cascade in gamma-radiation-induced cell cycle arrest. Mol. Cell Biol. 20, 4543-4552 (2000).
107. D. F. Stern, Tyrosine kinase signalling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2, 176-183 (2000).
108. K. L. Carraway and C. Sweeney, Localization and modulation of ErbB receptor tyrosine kinases. Curr. Opin. Cell Biol. 13, 125-130 (2001).
109. C. Sweeney and K. L. Carraway, 3rd, Ligand discrimination by ErbB receptors: Differential signaling through differential phosphorylation site usage. Oncogene 19, 5568-5573 (2000).
110. C. Cochet, G. N. Gill, J. Meisenhelder, J. A. Cooper and T. Hunter, C-kinase phosphorylates the epidermal growth factor receptor and reduces its epidermal growth factor-stimulated tyrosine protein kinase activity. J. Biol. Chem. 259, 2553-2558 (1984).
111. S. Cohen, The receptor for epidermal growth factor functions as a tyrosyl-specific kinase. Prog. Nucleic Acid. Res. Mol. Biol. 29, 245-247 (1983).
112. X. Zhang, E. Silva, D. Gershenson and M. C. Hung, Amplification and rearrangement of c-erb B proto-oncogenes in cancer of human female genital tract. Oncogene 4, 985-989 (1989).
113. N. H. Chow, S. H. Chan, T. S. Tzai, C. L. Ho and H. S. Liu, Expression profiles of erbb family receptors and prognosis in primary transitional cell carcinoma of the urinary bladder. Clin. Cancer Res. 7, 1957-1962 (2001).
114. C. K. Tang, X. Q. Gong, D. K. Moscatello, A. J. Wong and M. E Lippman, Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer. Cancer Res. 60, 3081-3087 (2000).
115. X. Y. Wang, D. I. Smith, L. Frederick and C. D. James, Analysis of EGF receptor amplicons reveals amplification of multiple expressed sequences. Oncogene 16, 191-195 (1998).
116. L. Frederick, G. Eley, X. Y. Wang and C. D. James, Analysis of genomic rearrangements associated with EGRFvIII expression suggests involvement of Alu repeat elements. Neuro-oncol 2, 159-163 (2000).
117. K. Zhang, J. Sun, N. Liu, D. Wen, D. Chang, A. Thomason and S. K. Yoshinaga, Transformation of NIH 3T3 cells by HER3 or HER4 receptors requires the presence of HER1 or HER2. J. Biol. Chem. 271, 3884-3890 (1996).
118. J. J. Hsuan, G. Panayotou and M. D. Waterfield, Structural basis for epidermal growth factor receptor function. Prog. Growth Factor Res. 1, 23-32 (1989).
119. G. C. Huang, X. Ouyang and R. J. Epstein, Proxy activation of protein ErbB2 by heterologous ligands implies a heterotetrameric mode of receptor tyrosine kinase interaction. Biochem. J. 331, 113-119 (1998).
120. X. Qian, C. M LeVea, J. K. Freeman, W. C. Dougall and M. I. Greene, Heterodimerization of epidermal growth factor receptor and wild-type or kinase-deficient Neu: A mechanism of interreceptor kinase activation and transphosphorylation. Proc. Natl. Acad. Sci. USA 91, 1500-1504 (1994).
121. N. G. Azios, F. J. Romero, M. C. Denton, J. K. Doherty and G. M. Clinton, Expression of herstatin, an autoinhibitor of HER-2/neu, inhibits transactivation of HER-3 by HER-2 and blocks EGF activation of the EGF receptor. Oncogene 20, 5199-5209 (2001).
122. S. Paik and C. Park, HER-2 and choice of adjuvant chemotherapy in breast cancer. Semin. Oncol. 28, 332-335 (2001).
123. N. Prenzel, O. M. Fischer, S. Streit, S. Hart and A. Ullrich, The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr. Relat. Cancer 8, 11-31 (2001).
124. J. Y. Yoo and A. W. Hamburger, The use of the yeast two hybrid system to evaluate ErbB-3 interactions with SH2 domain containing proteins. Biochem. Biophys. Res. Commun. 251, 903-906 (1998).
125. E. Tzahar, G. Levkowitz, D. Karunagaran, L. Yi, E. Peles, S. Lavi, D. Chang, N. Liu, A. Yayon and D. Wen, ErbB-3 and ErbB-4 function as the respective low and high affinity receptors of all Neu differentiation factor/heregulin isoforms. J. Biol. Chem. 269, 25226-25233 (1994).
126. H. Waterman, I. Alroy, S. Strano, R. Seger and Y. Yarden, The C-terminus of the kinase-defective neuregulin receptor ErbB-3 confers mitogenic superiority and dictates endocytic routing. EMBO J. 18, 3348-3358 (1999).
127. M. Offterdinger, S. M. Schneider, H. Huber and T. W. Grunt, Expression of c-erbB-4/HER4 is regulated in T47D breast carcinoma cells by retinoids and vitamin D3. Biochem. Biophys. Res. Commun. 258, 559-564 (1999).
128. K. L. Carraway, Involvement of the neuregulins and their receptors in cardiac and neural development. Bioessays 18, 263-266 (1996).
129. L. M. Gilmour, K. G. Macleod, A. McCaig, W. J. Gullick, J. F. Smyth and S. P. Langdon, Expression of erbB-4/HER-4 growth factor receptor isoforms in ovarian cancer. Cancer Res. 61, 2169-2176 (2001).
130. C. Sawyer, I. Hiles, M. Page, M. Crompton and C. Dean, Two erbB-4 transcripts are expressed in normal breast and in most breast cancers. Oncogene 17, 919-924 (1998).
131. S. Carter, K. L. Auer, M. Birrer, P. B. Fisher, R. K. Schmidt-Ullrich, K. Valerie, R. Mikkelsen and P. Dent, Inhibition of mitogen activated protein kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells. Oncogene 16, 2787-2796 (1998).
132. B. D. Kavanagh, P. Dent, R. K. Schmidt-Ullrich, P. Chen and R. B. Mikkelsen, Calcium-dependent stimulation of mitogen-activated protein kinase activity in A431 cells by low doses of ionizing radiation. Radiat. Res. 149, 579-587 (1998).
133. N. Balaban, J. Moni, M. Shannon, L. Dang, E. Murphy and T. Goldkorn, The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation. Biochim. Biophys. Acta 1314, 147-156 (1996).
134. S. Suy, W. B. Anderson, P. Dent, E. Chang and U. Kasid, Association of Grb2 with Sos and Ras with Raf-1 upon gamma irradiation of breast cancer cells. Oncogene 15, 53-61 (1997).
135. A. S. Levenson, D. A. Tonetti and V. C. Jordan, The estrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the estrogen receptor. Br. J. Cancer 77, 1812-1819 (1998).
136. J. Baselga, J. Mendelson, Y. M. Kim and A. Pandiella, Autocrine regulation of membrane transforming growth factor-α cleavage. J. Biol. Chem. 271, 3279-3284 (1996).
137. R. K. Schmidt-Ullrich, K. Valerie, W. Chan, D. E. Wazer and P. S. Lin, Expression of oestrogen receptor and transforming growth factor-α in MCF-7 cells after exposure to fractionated irradiation. Int. J. Radiat. Biol. 61, 405-415 (1992).
138. T. Putz, Z. Culig, I. E. Eder, C. Nessler-Menardi, G. Bartsch, H. Grunicke, F. Uberall and H. Klocker, Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor 1, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines. Cancer Res. 59, 227-233 (1999).
139. P. Dent, D. B. Reardon, J. S. Park, G. Bowers, C. Logsdon, K. Valerie and R. K. Schmidt-Ullrich, Radiation-induced activations of the epidermal growth factor receptor and the mitogen activated protein kinase pathway via transforming growth factor a in autocrine-regulated carcinoma cells. Mol. Biol. Cell 10, 2493-2506 (1999).
140. M. Hagan and P. Dent, Inhibition of the MAPK pathway radiosensitizes DU145 prostate carcinoma cells. Radiat. Res. 153, 371-381 (2000).
141. A. Schulze, K. Lehmann, H. B. Jefferies, M. McMahon and J. Downward, Analysis of the transcriptional program induced by Raf in epithelial cells. Genes Dev. 15, 981-994. (2001).
142. I. Baba, S. Shirasawa, R. Iwamoto, K. Okumura, T. Tsunoda, M. Nishioka, K. Fukuyama, K. Yamamoto, E. Mekada and T. Sasazuki, Involvement of deregulated epiregulin expression in tumorigenesis in vivo through activated Ki-Ras signaling pathway in human colon cancer cells. Cancer Res. 60, 6886-6889 (2000).
143. G. Bowers, D. Reardon, T. Hewitt, P. Dent, R. B. Mikkelsen, K. Valerie, G. Lammering, C. Amir and R. K. Schmidt-Ullrich, The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 20, 1388-1397 (2001).
144. J. N. Contessa, J. Hampton, G. Lammering, R. B. Mikkelsen, P. Dent, K. Valerie and R. K. Schmidt-Ullrich, Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 21, 4032-4041 (2002).
145. S. Grant, L. Qiao and P. Dent, Roles of ERBB family receptor tyrosine kinases, and downstream signaling pathways, in the control of cell growth and survival. Front. Biosci. 7, 376-389 (2002).
146. R. K. Schmidt-Ullrich, P. Dent, S. Grant, R. B. Mikkelsen and K. Valerie, Signal transduction and cellular radiation responses. Radiat. Res. 153, 245-257 (2000).
147. J. Jakus and W. A. Yeudall, Growth inhibitory concentrations of EGF induce p21 (WAF1/Cip1) and alter cell cycle control in squamous carcinoma cells. Oncogene 12, 2369-2376 (1996).
148. W. F. Fong, C. H. Leung, W. Lam, N. S. Wong and S. H. Cheng, Epidermal growth factor induces Gadd45 (growth arrest and DNA damage inducible protein) expression in A431 cells. Biochim. Biophys. Acta 1517, 250-256 (2001).
149. J. Mendelsohn, The epidermal growth factor receptor as a target for cancer therapy. Endocr. Relat. Cancer 8, 3-9 (2001).
150. J. S. Ross and J. A. Fletcher, The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells 16, 413-428 (1998).
151. K. Mishima, T. G. Johns, R. B. Luwor, A. M. Scott, E. Stockert, A. A. Jungbluth, X. D. Ji, P. Suvarna, J. R. Voland and W. K. Cavenee, Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor. Cancer Res. 61, 5349-5354 (2001).
152. C. Erlichman, S. A. Boerner, C. G. Hallgren, R. Spieker, X. Y. Wang, C. D. James, G. L. Scheffer, M. Maliepaard, D. D. Ross and S. H. Kaufmann, The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. Cancer Res. 61, 739-748 (2001).
153. C. J. Bruns, C. C. Solorzano, M. T. Harbison, S. Ozawa, R. Tsan, D. Fan, J. Abbruzzese, P. Traxler, E. Buchdunger and I. J. Fidler, Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. Cancer Res. 60, 2926-2935 (2000).
154. K. Suzuki, S. Kodama and M. Watanabe, Extremely low-dose ionizing radiation causes activation of mitogen-activated protein kinase pathway and enhances proliferation of normal human diploid cells. Cancer Res. 61, 5396-5401 (2001).
155. H. Wakita and M. Takigawa, Activation of epidermal growth factor receptor promotes late terminal differentiation of cell-matrix interaction-disrupted keratinocytes. J. Biol. Chem. 274, 37285-37291 (1999).
156. A. J. Barker, K. H. Gibson, W. Grundy, A. A. Godfrey, J. J. Barlow, M. P. Healy, J. R. Woodburn, S. E. Ashton, B. J. Curry and L. Richards, Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the
157. P. W. Vincent, A. J. Bridges, D. J. Dykes, D. W. Fry, W. R. Leopold, S. J. Patmore, B. J. Roberts, S. Rose, V. Sherwood and W. L. Elliott, Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against human tumor xenografts. Cancer Chemother. Pharmacol. 45, 231-238 (2000).
158. M. Hidalgo, L. L. Siu, J. Nemunaitis, J. Rizzo, L. A. Hammond, C. Takimoto, S. G. Eckhardt, A. Tolcher, C. D. Britten and E. K. Rowinsky, Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19, 3267-3279 (2001).
159. A. Fernandes, A. W. Hamburger and B. I. Gerwin, ErbB-2 kinase is required for constitutive stat 3 activation in malignant human lung epithelial cells. Int. J. Cancer 83, 564-570 (1999).
160. S. Yeh, H. K. Lin, H. Y. Kang, T. H. Thin, M. F. Lin and C. Chang, From HER2/Neu signal cascade to androgen receptor and its coactivators: A novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. USA 96, 5458-5463 (1999).
161. D. B. Reardon, J. N. Contessa, R. B. Mikkelsen, K. Valerie, C. Amir, P. Dent and R. K. Schmidt-Ullrich, Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 18, 4756-4766 (1999).
162. F. E. Jones and D. F. Stern. Expression of dominant-negative ErbB2 in the mammary gland of transgenic mice reveals a role in lobuloalveolar development and lactation. Oncogene 18, 3481-3490 (1999).
163. T. G. Ram, M. E. Schelling and H. L. Hosick, Blocking HER-2/ HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification. Cell. Growth. Differ. 11, 173-183 (2000).
164. J. S. Park, S. Carter, D. B. Reardon, R. K. Schmidt-Ullrich, P. Dent and P. B. Fisher, Roles for basal and stimulated p21(Cip-1/WAF1/MDA6) expression and mitogen-activated protein kinase signaling in radiation-induced cell cycle checkpoint control in carcinoma cells. Mol. Biol. Cell 10, 4231-4246 (1999).
165. J. Mendelsohn and J. Baselga, The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550-6565 (2000).
166. Y. Yarden and M. X. Sliwkowski, Untangling the ErbB signalling network. Nat. Rev. Mol. Cell. Biol. 2, 127-137 (2001).
167. R. S. Herbst and C. J. Langer. Epidermal growth factor receptors as a target for cancer treatment: The emerging role of IMC-C225 in the treatment of lung and head and neck cancers. Semin. Oncol. 29, 27-36 (2002).
168. J. Baselga and J. Albanell, Mechanism of action of anti-HER2 monoclonal antibodies. Ann. Oncol. 12, 35-41 (2001).
169. H. J. Burstein, I. Kuter, S. M. Campos, R. S. Gelman, L. Tribou, L. M. Parker, J. Manola, J. Younger, U. Matulonis and E. P. Winer, Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J. Clin. Oncol. 19, 2722-2730 (2001).
170. M. D. Pegram, A. Lopez, G. Konecny and D. J. Slamon, Trastuzumab and chemotherapeutics: Drug interactions and synergies. Semin. Oncol. 27, 21-25 (2000).
171. S. Nasu, K. K. Ang, Z. Fan and L. Milas, C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys. 51, 474-477 (2001).
172. J. Baselga, D. Pfister, M. R. Cooper, R. Cohen, B. Burtness, M. Bos, G. D'Andrea, A. Seidman, L. Norton and J. Mendelsohn, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol. 18, 904-914 (2000).
173. R. B. Luwor, T. G. Johns, C. Murone, H. J. Huang, W. K. Cavenee, G. Ritter, L. J. Old, A. W. Burgess and A. M. Scott, Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. 61, 5355-5361 (2001).
174. W. A. Denny, The 4-anilinoquinazoline class of inhibitors of the erbB family of receptor tyrosine kinases. Farmaco 56, 51-56 (2001).
175. A. J. Bridges, The rationale and strategy used to develop a series of highly potent, irreversible, inhibitors of the epidermal growth factor receptor family of tyrosine kinases. Curr. Med. Chem. 6, 825-843 (1999).
176. M. Bos, J. Mendelsohn, Y. M. Kim, J. Albanell, D. W. Fry and J. Baselga, PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner. Clin. Cancer Res. 3, 2099-2106 (1997).
177. R. Pinkas-Kramarski, A. E. Lenferink, S. S. Bacus, L. Lyass, M. L. van de Poll, L. N. Klapper, E. Tzahar, M. Sela, E. J. van Zoelen and Y. Yarden, The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. Oncogene 16, 1249-1258 (1998).
178. C. M. Tsai, A. Levitzki, L. H. Wu, K. T. Chang, C. C. Cheng, A. Gazit and R. P. Perng, Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 56, 1068-1074 (1996).
179. G. S. Rao, S. Murray and S. P. Ethier, Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int. J. Radiat. Oncol. Biol. Phys. 48, 1519-1528 (2000).
180. J. M. Nelson and D. W. Fry, Akt, MAPK (Erk1/2), and p38 act in concert to promote apoptosis in response to ErbB receptor family inhibition. J. Biol. Chem. 276, 14842-14847 (2001).
181. F. M. Sirotnak, M. F. Zakowski, V. A. Miller, H. I. Scher and M. G. Kris, Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin. Cancer Res. 6, 4885-4892 (2000).
182. R. K. Schmidt-Ullrich, K. Valerie, P. B. Fogleman and J. Walters, Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat. Res. 145, 81-85 (1996).
183. J. N. Contessa, D. B. Reardon, D. Todd, P. Dent, R. B. Mikkelsen, K. Valerie, G. D. Bowers and R. K. Schmidt-Ullrich, The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin. Cancer Res. 5, 405-411 (1999).
184. G. Lammering, T. H. Hewit, W. T. Hawkins, J. N. Contessa, D. B. Reardon, P. S. Lin, K. Valerie, P. Dent, R. B. Mikkelsen and R. K. Schmidt-Ullrich, Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J. Natl. Cancer Inst. 93, 921-929 (2001).
185. G. Lammering, K. Valerie, P. S. Lin, R. B. Mikkelsen, J. N. Contessa, J. P. Feden, J. Farnsworth, P. Dent and R. K. Schmidt-Ullrich, Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin. Cancer Res. 7, 682-690 (2001).
186. F. Ciardiello, R. Caputo, T. Troiani, G. Borriello, E. R. Kandimalla, S. Agrawal, J. Mendelsohn, A. R. Bianco and G. Tortora, Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int. J. Cancer 93, 172-178 (2001).
187. H. Eichholtz-Wirth and D. Sagan, Altered signaling of TNFα-TNFR1 and SODD/BAG4 is responsible for radioresistance in human HT-R15 cells. Anticancer Res. 22, 235-240 (2002).
188. F. Legue, N. Guitton, V. Brouazin-Jousseaume, S. Colleu-Durel, K. Nourgalieva and C. Chenal, IL-6 a key cytokine in in vitro and in vivo response of Sertoli cells to external gamma irradiation. Cytokine 16, 232-238 (2001).
189. Z. Ma, D. J. Webb, M. Jo and S. L. Gonias, Endogenously produced urokinase-type plasminogen activator is a major determinant of the basal level of activated ERK/MAP kinase and prevents apoptosis in MDA-MB-231 breast cancer cells. J. Cell Sci. 114, 3387-3396 (2001).
190. R. Iyer and B. E. Lehnert, Factors underlying the cell growth-related bystander responses to alpha particles. Cancer Res. 60, 1290-1298 (2000).
191. K. Rutault, C. A. Hazzalin and L. C. Mahadevan, Combinations of ERK and p38 MAPK inhibitors ablate tumor necrosis factor-alpha (TNF-α) mRNA induction. Evidence for selective destabilization of TNF-α transcripts. J. Biol. Chem. 276, 6666-6674 (2001).
192. S. Basu, K. R. Rosenzweig, M. Youmell and B. D. Price, The DNA-dependent protein kinase participates in the activation of NFκB following DNA damage. Biochem. Biophys. Res. Commun. 247, 79-83 (1998).
193. Y. Miyamoto, R. Hosotani, R. Doi, M. Wada, J. Ida, S. Tsuji, M. Kawaguchi, S. Nakajima, H. Kobayashi and M. Imamura, Interleukin-6 inhibits radiation induced apoptosis in pancreatic cancer cells. Anticancer Res. 21, 2449-2456 (2001).
194. T. D. Chung, J. J. Yu, T. A. Kong, M. T. Spiotto and J. M. Lin, Interleukin-6 activates phosphatidylinositol-3 kinase, which inhibits apoptosis in human prostate cancer cell lines. Prostate 42, 1-7 (2000).
195. D. Zhou, T. Yu, G. Chen, S. A. Brown, Z. Yu, M. P. Mattson and J. S. Thompson, Effects of NF-κB1 (p50) targeted gene disruption on ionizing radiation-induced NF-κB activation and TNFα, IL-1α, IL-1B and IL-6 mRNA expression in vivo. Int. J. Radiat. Biol. 77, 763-772 (2001).
196. G. F. Baxter, M. M. Mocanu, B. K. Brar, D. S. Latchman and D. M. Yellon, Cardioprotective effects of transforming growth factor-betal during early reoxygenation or reperfusion are mediated by p42/p44 MAPK. J. Cardiovasc. Pharmacol. 38, 930-939 (2001).
197. R. S. Muraoka, N. Dumont, C. A. Ritter, T. C. Dugger, D. M. Brantley, J. Chen, E. Easterly, L. R. Roebuck, S. Ryan and C. L. Arteaga, Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J. Clin. Invest. 109, 1551-1559 (2002).
198. N. Bulus and J. A. Barnard, Heparin binding epidermal growth factor-like growth factor is a transforming growth factor beta-regulated gene in intestinal epithelial cells. Biochem. Biophys. Res. Commun. 264, 808-812 (1999).
199. B. Saile, N. Matthes, E. Armouche, K. Neubauer and G. Ramadori, The bcl, NFκB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-β or TNF-α on activated hepatic stellate cells. Eur. J. Cell Biol. 80, 554-561 (2001).
200. K. Lehmann, E. Janda, C. E. Pierreux, M. Rytomaa, A. Schulze, M. McMahon, C. S. Hill, H. Beug and J. Downward, Raf induces TGFβ production while blocking its apoptotic but not invasive responses: a mechanism leading to increased malignancy in epithelial cells. Genes Dev. 14, 2610-2622 (2000).
201. R. H. Chen, Y. H. Su, R. L. Chuang and T. Y. Chang, Suppression of transforming growth factor-beta-induced apoptosis through a phosphatidylinositol 3-kinase/Akt-dependent pathway. Oncogene 17, 1959-1968 (1998).
202. R. Garcia, T. L. Bowman, G. Niu, H. Yu, S. Minton, C. A. MuroCacho, C. E. Cox, R. Falcone, R. Fairclough and R. Jove, Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene 20, 2499-2513 (2001).
203. B. Liu, M. Fang, Y. Lu, Y. Lu, G. B. Mills and Z. Fan, Involvement of JNK-mediated pathway in EGF-mediated protection against paclitaxel-induced apoptosis in SiHa human cervical cancer cells. Br. J. Cancer 85, 303-311 (2001).
204. J. T. Lee and J. A. McCubrey, The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16, 486-507 (2002).
205. J. C. Reed, Dysregulation of apoptosis in cancer. J. Clin. Oncol. 17, 2941-2953 (1999).
206. L. Qiao, E. Studer, K. Leach, R. McKinstry, S. Gupta, R. Decker, R. Kukreja, K. Valerie, P. Nagarkatti and P. Dent, Deoxycholic acid (DCA) causes ligand-independent activation of epidermal growth factor receptor (EGFR) and FAS receptor in primary hepatocytes: Inhibition of EGFR/mitogen-activated protein kinase-signaling module enhances DCA-induced apoptosis. Mol. Biol. Cell 12, 2629-2645 (2001).
207. M. Sarker, C. Ruiz-Ruiz, G. Robledo and A. Lopez-Rivas, Stimulation of the mitogen-activated protein kinase pathway antagonizes TRAIL-induced apoptosis downstream of BID cleavage in human breast cancer MCF-7 cells. Oncogene 21, 4323-4327 (2002).
208. S. Li, Y. Zhao, X. He, T. H. Kim, D. K. Kuharsky, H. Rabinowich, J. Chen, C. Du and X. M. Yin, Relief of extrinsic pathway inhibition by the bid-dependent mitochondrial release of Smac in Fas-mediated hepatocyte apoptosis. J. Biol. Chem. 277, 26912-26920 (2002)
209. S. H. Kaufmann and W. C. Earnshaw, Induction of apoptosis by cancer chemotherapy. Exp. Cell Res. 256, 42-49 (2000).
210. N. V. Guseva, A. F. Taghiyev, O. W. Rokhlin and M. B. Cohen, Contribution of death receptor and mitochondrial pathways to Fas-mediated apoptosis in the prostatic carcinoma cell line PC3. Prostate 51, 231-240 (2002).
211. S. Kitada, I. M. Pedersen, A. D. Schimmer and J. C. Reed, Dysregulation of apoptosis genes in hematopoietic malignancies. Oncogene 21, 3459-3474 (2002).
212. G. S. Salvesen and C. S. Duckett, Apoptosis: IAP proteins: Blocking the road to death's door. Nat. Rev. Mol. Cell Biol. 6, 401-410 (2002).
213. J. Albanell, J. Codony-Servat, F. Rojo, J. M. Del Campo, S. Sauleda, J. Anido, G. Raspall, J. Giralt, J. Rosello and J. Baselga, Activated extracellular signal-regulated kinases: Association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res. 61, 6500-6510 (2001).
214. Z. Q. Xiao and A. P. Majumdar, Increased in vitro activation of EGFR by membrane-bound TGF-α from gastric and colonic mucosa of aged rats. Am. J. Physiol. Gastrointest. Liver Physiol. 281, G111-G116 (2001).
215. B. P. Zhou, M. C. Hu, S. A. Miller, Z. Yu, W. Xia, S. Y. Lin and M. C. Hung, HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-κB pathway. J. Biol. Chem. 275, 8027-8031 (2000).
216. V. Kainulainen, M. Sundvall, J. A. Maatta, E. Santiestevan, M. Klagsbrun and K. Elenius, A natural ErbB4 isoform that does not activate phosphoinositide 3-kinase mediates proliferation but not survival or chemotaxis. J. Biol. Chem. 27, 8641-8649 (2000).
217. J. M. Daly, M. A. Olayioye, A. M. Wong, R. Neve, H. A. Lane, F. G. Maurer and N. E. Hynes, NDF/heregulin-induced cell cycle changes and apoptosis in breast tumour cells: Role of PI3 kinase and p38 MAP kinase pathways. Oncogene 18, 3440-3451 (1999).
218. Y. Leverrier, J. Thomas, A. L. Mathieu, W. Low, B. Blanquier and J. Marvel, Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ. 6, 290-296 (1999).
219. M. L. Kuo, S. E. Chuang, M. T. Lin and S. Y. Yang, The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 20, 677-685 (2001).
220. D. J. Panka, T. Mano, T. Suhara, K. Walsh and J. W. Mier, Phosphatidylinositol 3-kinase/Akt activity regulates c-FLIP expression in tumor cells. J. Biol. Chem. 276, 6893-6896 (2001).
221. T. Suhara, T. Mano, B. E. Oliveira and K. Walsh, Phosphatidylinositol 3-kinase/Akt signaling controls endothelial cell sensitivity to Fas-mediated apoptosis via regulation of FLICE-inhibitory protein (FLIP). Circ. Res. 89, 13-19 (2001).
222. E. Fujita, A. Jinbo, H. Matuzaki, H. Konishi, U. Kikkawa and T. Momoi, Akt phosphorylation site found in human caspase-9 is absent in mouse caspase-9. Biochem. Biophys. Res. Commun. 264, 550-555 (1999).
223. Y. Li, G. I. Tennekoon, M. Birnbaum, M. A. Marchionni and J. L. Rutkowski, Neuregulin signaling through a PI3K/Akt/Bad pathway in Schwann cell survival. Mol. Cell. Neurosci. 17, 761-767 (2001).
224. S. Pianetti, M. Arsura, R. Romieu-Mourez, R. J. Coffey and G. E. Sonenshein, Her-2/neu overexpression induces NF-κB via a PI3-kinase/Akt pathway involving calpain-mediated degradation of IκB-alpha that can be inhibited by the tumor suppressor PTEN. Oncogene 20, 1287-1299 (2001).
225. M. Cuello, S. A. Ettenberg, A. S. Clark, M. M. Keane, R. H. Posner, M. M. Nau, P. A. Dennis and S. Lipkowitz, Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 61, 4892-4900 (2001).
226. A. K. Gupta, V. J. Bakanauskas, G. J. Cerniglia, Y. Cheng, E. J. Bernhard, R. J. Muschel and W. G. McKenna, The Ras radiation resistance pathway. Cancer Res. 61, 4278-4782 (2001).
227. A. K. Gupta, W. G. McKenna, C. N. Weber, M. D. Feldman, J. D. Goldsmith, R. Mick, M. Machtay, D. I. Rosenthal, V. J. Bakanauskas and R. J. Muschel, Local recurrence in head and neck cancer: Relationship to radiation resistance and signal transduction. Clin. Cancer Res. 8, 885-892 (2002).
228. A. K. Gupta, E. J. Bernhard, V. J. Bakanauskas, J. Wu, R. J. Muschel and W. G. McKenna, RAS-mediated radiation resistance is not linked to MAP kinase activation in two bladder carcinoma cell lines. Radiat. Res. 154, 64-72 (2000).
229. 2/M checkpoint arrest in cells exposed to ionizing radiation. J. Biol. Chem. 274, 2732-2742 (1999).
230. 2-M arrest. Cell Growth Differ. 13, 237-246 (2002).
231. 2 phase after 2 Gy gamma irradiation is faster in radiosensitive human cells with high expression of the RAF1 proto-oncogene. Radiat. Res. 146, 485-493 (1996).
232. O. E. Pardo, A. Arcaro, G. Salerno, S. Raguz, J. Downward and M. J. Seckl, Fibroblast growth factor-2 induces translational regulation of Bcl-XL and Bcl-2 via a MEK-dependent pathway: Correlation with resistance to etoposide-induced apoptosis. J. Biol. Chem. 277, 12040-12046 (2002).
233. D. Tang, D. Wu, A. Hirao, J. M. Lahti, L. Liu, B. Mazza, V. J. Kidd, T. W. Mak and A. J. Ingram, ERK activation mediates cell cycle arrest and apoptosis after DNA damage independently of p53. J. Biol. Chem. 277, 12710-12717 (2002).
234. D. Kitagawa, S. Tanemura, S. Ohata, N. Shimizu, J. Seo, G. Nishitai, T. Watanabe, K. Nakagawa, H. Kishimoto and T. Katada, Activation of extracellular signal-regulated kinase by ultraviolet is mediated through Src-dependent epidermal growth factor receptor phosphorylation. Its implication in an anti-apoptotic function. J. Biol. Chem. 277, 366-371 (2002).
235. M. Jost, T. M. Huggett, C. Kari, L. H. Boise and U. Rodeck, Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-xL expression through a MEK-dependent pathway. J. Biol. Chem. 276, 6320-6326 (2001).
236. M. J. Boucher, J. Morisset, P. H. Vachon, J. C. Reed, J. Laine and N. Rivard, MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-XL, and Mcl-1 and promotes survival of human pancreatic cancer cells. J. Cell. Biochem. 79, 355-369 (2000).
237. F. Aoudjit and K. Vuori, Matrix attachment regulates Fas-induced apoptosis in endothelial cells: A role for c-flip and implications for anoikis. J. Cell. Biol. 152, 633-643 (2001).
238. A. Yacoub, J. S. Park, L. Qiao, P. Dent and M. P. Hagan, MAPK dependence of DNA damage repair: Ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int. J. Radiat. Biol. 77, 1067-1078 (2001).
239. A. Riccio, S. Ahn, C. M. Davenport, J. A. Blendy and D. D. Ginty, Mediation by a CREB family transcription factor of NGF-dependent survival of sympathetic neurons. Science 286, 2358-2361 (1999).
240. D. De Cesare, S. Jacquot, A. Hanauer and P. Sassone-Corsi, Rsk-2 activity is necessary for epidermal growth factor-induced phosphorylation of CREB protein and transcription of c-fos gene. Proc. Natl. Acad. Sci. USA 95, 12202-12207 (1998).
241. P. Erhardt, E. J. Schremser and G. M. Cooper, B-Raf inhibits programmed cell death downstream of cytochrome c release from mitochondria by activating the MEK/Erk pathway. Mol. Cell. Biol. 19, 5308-5315 (1999).
242. B. W. Park, H. T. Zhang, C. Wu, A. Berezov, X. Zhang, R. Dua, Q. Wang, G. Kao, D. M. O'Rourke and R. Murali, Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/neu tyrosine kinases in vitro and in vivo. Nat. Biotechnol. 18, 194-198 (2000).
243. P. N. Munster, D. C. Marchion, A. D. Basso and N. Rosen, Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3′-kinase-AKT-dependent pathway. Cancer Res. 62, 3132-3137 (2002).
244. M. Jung and A. Dritschilo, NF-κB signaling pathway as a target for human tumor radiosensitization. Semin. Radiat. Oncol. 11, 346-351 (2001).
245. J. S. Russell, U. Raju, G. J. Gumin, F. F. Lang, D. R. Wilson, T. Huet and P. J. Tofilon, Inhibition of radiation-induced nuclear factor-κB activation by an anti-Ras single-chain antibody fragment: Lack of involvement in radiosensitization. Cancer Res. 62, 2318-2326 (2002).
246. P. Bhat-Nakshatri, C. J. Sweeney and H. Nakshatri, Identification of signal transduction pathways involved in constitutive NF-κB activation in breast cancer cells. Oncogene 21, 2066-2078 (2002).
247. J. Troppmair, J. Hartkamp and U. R. Rapp, Activation of NF-κB by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade. Oncogene 17, 685-690 (1998).
248. L. M. Tuyt, W. H. Dokter, K. Birkenkamp, S. B. Koopmans, C. Lummen, W. Kruijer and E. Vellenga, Extracellular-regulated kinase 1/2, Jun N-terminal kinase, and c-Jun are involved in NF-κB-dependent IL-6 expression in human monocytes. J. Immunol. 162, 4893-4902 (1999).
249. M. Barradas, A. Monjas, M. T. Diaz-Meco, M. Serrano and J. Moscat, The down regulation of the pro-apoptotic protein Par-4 is critical for Ras-induced survival and tumor progression. EMBO J. 18, 6362-6369 (1999).
250. S. G. Qiu, N. El-Guendy, S. Krishnan and V. M. Rangnekar, Negative regulation of Par-4 by oncogenic Ras is essential for cellular transformation. Oncogene 18, 7115-7123 (1999).
251. S. Camandola and M. P. Mattson, Pro-apoptotic action of PAR-4 involves inhibition of NF-κB activity and suppression of BCL-2 expression. J. Neurosci. Res. 61, 134-139 (2000).
252. M. T. Diaz-Meco, M. J. Lallena, A. Monjas, S. Frutos and J. Moscat, Inactivation of the inhibitory κB protein kinase/nuclear factor κB pathway by Par-4 expression potentiates tumor necrosis factor alpha-induced apoptosis. J. Biol. Chem. 274, 19606-19612 (1999).
253. Y. M. Wang, M. L. Seibenhener, M. L. Vandenplas and M. W. Wooten, Atypical PKC zeta is activated by ceramide, resulting in coactivation of NF-κB/JNK kinase and cell survival. J. Neurosci. Res. 55, 293-302 (1999).
254. D. Chendil, A. Das, S. Dey, M. Mohiuddin and M. M. Ahmed, Par-4, A pro-apoptotic gene, inhibits radiation-induced NFkB activity and Bcl-2 expression leading to induction of radiosensitivity in human prostate cancer cells PC-3. Cancer Biol. Ther. 2, 152-162 (2002).
255. M. Chakraborty, S. G. Qiu, K. M. Vasudevan and V. M. Rangnekar, Par-4 drives trafficking and activation of Fas and Fas1 to induce prostate cancer cell apoptosis and tumor regression. Cancer Res. 61, 7255-7263 (2001).
256. C. Mothersill, C. B. Seymour and M. C. Joiner, Relationship between radiation-induced low-dose hypersensitivity and the bystander effect. Radiat. Res. 157, 526-532 (2002).